Nimotuzumab enhances temozolomide‐induced growth suppression of glioma cells expressing mutant EGFR in vivo

A mutant form of epidermal growth factor receptor (EGFR), EGFRvIII, is common in glioblastoma (GBM) and confers enhanced tumorigenic activity and drug resistance. Nimotuzumab, an anti‐EGFR antibody, has shown preclinical and clinical activity to GBM, but its specific activity against EGFRvIII has no...

Descripción completa

Detalles Bibliográficos
Autores principales: Nitta, Yusuke, Shimizu, Saki, Shishido‐Hara, Yukiko, Suzuki, Kaori, Shiokawa, Yoshiaki, Nagane, Motoo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4799951/
https://www.ncbi.nlm.nih.gov/pubmed/26778701
http://dx.doi.org/10.1002/cam4.614

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4799951/
https://www.ncbi.nlm.nih.gov/pubmed/26778701
http://dx.doi.org/10.1002/cam4.614

Ejemplares similares